Coverage rates of the children vaccination programme in Greenland.
Coverage rates of the children vaccination programme in Greenland. Int J Circumpolar Health. 2020 Dec;79(1):1721983 Authors: Albertsen N, Lynge AR, Skovgaard N, Olesen JS, Pedersen ML Abstract In order to estimate the current coverage rate among all children in Greenland, we conducted an observational cross-sectional study identifying all children in Greenland eligible for a vaccination between 1 March 2018 and 16 June 2019. we found an overall national coverage of 85.4%. The national coverage for the vaccinations given at birth was 97.1%, dropping to 94.3%, 87.7% and 83.6% at ages 3, 5 and 12 months. Among children eligible for the Measles, Mumps and Rubella-vaccinations, the national coverage was 76.9% for children aged 15 months and 64.1% for children aged 4 years, but dropping to 40.9% in the districts. At preschool, the national coverage was 79.9%. Among the 12-year-old, the national coverages of the two vaccinations against Human Papilloma Virus were 88.4% and 71.6%, respectively, and for the three Hepatitis B-vaccinations 89.8%, 84.1% and 69.6%. A subgroup-analysis and test of an SMS-reminder system in Nuuk improved the coverage from 57.8% to 75.5% locally. Overall, we found a high national coverage rate among the newborn in Greenland. The national coverage rates of the remaining vaccinations were below the WHO-recommendations, however with great regional differences.Abbreviations: CVP: Children Vaccination Programme; BCG: Bacille Calmette-Guerin; ...
Publication date: Available online 9 October 2020Source: Pathology - Research and PracticeAuthor(s): Borislav A. Alexiev, Farres Obeidin, Daniel N. Johnson, Brian S. Finkelman, Rebecca Prince, Shaan N. Somani, Esther Cheng, Sandeep Samant
Publication date: Available online 10 October 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Pramod Kumar, Anand Kulkarni, Mithun Sharma, Padaki Nagaraja Rao
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]
Emergency-use authorizations, a formerly obscure corner of regulatory law, have become a centerpiece of the government ’s response to the pandemic.
The use of an immune-system stimulant harvested from shark liver oil in the development of some coronavirus vaccines has animal conservationists pressing for alternatives.(Image credit: Reinhard Dirscherl/ullstein bild via Getty Images)
We report the rare case of a patient co-existing NS and DLBCL. DLBCL might be pathogenesis of NS; the findings are supported by the presence of MN, an underlying malignancy (DLBCL), and the lack of anti-PLA2R antibodies. Although further investigation is warranted, our case suggests that DLBCL is a possible cause of secondary MN. PMID: 33028760 [PubMed - in process]
In conclusion, our multidisciplinary approach to prevent de novo hepatitis B is considered useful. PMID: 33028756 [PubMed - in process]
Discussion Vaccines are a mainstay of infectious disease prevention and health promotion. Infants, children and adults benefit from vaccines the most when they are given on the recommended schedules. However there are times when this is not possible as children come to the physician a little early, or a little late, or had unavailable records and so received addition vaccine, etc. There are many questions that arise because of these timing issues such as the one above. Standard vaccine schedules can be reviewed here. Commonly administered vaccines includes: Live-attenuated vaccines Cholera Measles, mumps, rubella (MMR ...
Authors: Albertsen N, Fencker IM, Noasen HE, Pedersen ML Abstract The children immunisation programme in Greenland correlates to the one in Denmark with the addition of the Bacille Calmette-Guerin (BCG)-vaccine and the immunisation against Hepatitis B (HBV). The immunisation rate among children in Greenland has been and is currently unknown and this study aims to estimate the immunisation rates among children in Nuuk from 1 July 2015 until 30 June 2016. We did an observational cross-sectional study based on a statistical extraction identifying all children in Nuuk eligible for an immunization in the children immuni...
More News: Cervical Cancer Vaccine | Children | Diphtheria | Hepatitis | Hepatitis B | Hepatitis Vaccine | Human Papillomavirus (HPV) | Influenza | Influenza Vaccine | International Medicine & Public Health | Measles | Measles Vaccine | Mumps | Mumps Vaccine | Polio | Polio Vaccine | Rubella | Rubella Vaccine | Study | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | WHO | Whooping Cough (Pertussis) Vaccine